Full Archive

Carbon Ion Radiation Therapy for Mesothelioma

A specific type of radiation could be useful for the treatment of mesothelioma. Carbon-ion beam irradiation along with the chemotherapy drug cisplatin could potentially stop the growth of pleural mesothelioma tumors. Research was conducted at a carbon ion center in Chiba, Japan and results have been published to the American[…]

Read More »

Legacy Asbestos More Dangerous than Previously Thought

A United Kingdom study is showing the dangers of legacy asbestos. Asbestos that remains in commercial and residential buildings can be more dangerous than previously thought. Researchers from the study found that two-thirds of the asbestos still in buildings was old enough or damaged enough to release fibers into the[…]

Read More »

Pleurectomy and Decortication is the Best Option for Bicavity Surgery on Peritoneal Mesothelioma

Patients with thoracic and abdominal mesothelioma can extend survival when they are given aggressive surgery. This news came from a study at Baylor College of Medicine in Houston. When patients are given bicavity cytoreductive surgery, they had a median survival of 58.2 months.  The results were published in December in[…]

Read More »

A Treatment Involving Checkpoint Inhibitors Before Surgery is Showing Promising Results for Mesothelioma

Immunotherapy before aggressive surgery shows great promise for pleural mesothelioma. The combination has shown that it can improve survival for a group of patients with pleural mesothelioma in a phase II study at Baylor College of Medicine. The treatment uses two immune checkpoint inhibitors, durvalumab and tremelimumab. The two drugs[…]

Read More »

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma (HIT-Meso)

Primary Outcome Measures Progression free survival [ Time Frame: From randomisation up to 2 years of follow up ] Defined as the time from randomisation to the date of disease progression Overall survival [ Time Frame: From randomisation up to 2 years of follow up ] defined as the time from randomisation to the date of death from[…]

Read More »

Timely Treatment for Mesothelioma Could Improve Survival

It is best to treat peritoneal mesothelioma as soon as possible. Waiting to receive treatment could prevent a patient from living longer than possible. Information from a study looking at treatment start times was published in the Journal of Gastrointestinal Surgery in November. Researchers observed patients who either received treatment[…]

Read More »

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

Primary Outcome Measures Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD) [ Time Frame: 28 days during 1st cycle ] Determine the MTD and/or MAD of anti GP88 monoclonal antibody (AG-01) in subjects with advanced/refractory solid tumor malignancies for which no effective therapies exist. Antitumor Activity of AG-01 by Overall Response Rate (ORR)[…]

Read More »

Mesothelioma Rates Increased Over a 30 Year Period

Mesothelioma diagnoses have almost doubled in the last 30 years, highlighting the need for better care and more ways to regulate and reduce asbestos exposure. There were around 35,000 people diagnosed with mesothelioma in 2019, while in 1990 there were around 19,000 people diagnosed. This information was released by the[…]

Read More »

Study Found Lung Removing Surgery for Mesothelioma Can be More Effective in Some Patients

The most aggressive surgery for mesothelioma could be more beneficial for patients with the disease. The more aggressive surgery is called an extrapleural pneumonectomy (EPP), which involves removing the lung. The other surgery, pleurectomy and decortication (P/D), spares the lung and only removes the lining of the lung and visible[…]

Read More »

Gavo-Cel Moving to Phase II Trial for Mesothelioma

A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of[…]

Read More »